Skip to Content
IJMSInternational Journal of Molecular Sciences
  • Review
  • Open Access

24 May 2022

Virulence Factors of Candida spp. and Host Immune Response Important in the Pathogenesis of Vulvovaginal Candidiasis

,
and
Department of Microbiology, Faculty of Medicine, Wrocław Medical University, 50-368 Wrocław, Poland
*
Author to whom correspondence should be addressed.

Abstract

Vulvovaginal candidiasis (VVC) is one of the most common types of vaginal infections in women around the world and is often underestimated by both patients and doctors. Research on the pathogenesis of fungal vaginal infections over the last 20 years has resulted in a closer understanding of the virulence factors involved in Candida epithelial invasion and their mechanisms of action. Recently, attention was drawn to the enormous complexity of the interaction between yeast-like fungi and host cells, as well as the level of complexity of the host’s response to infection and their impact on the course and treatment of VVC. Our work provides a broad description of already known and some new reports on Candida virulence factors (such as phenotypic switching or biofilm formation capacity) and their importance for tissue invasion in VVC. At the same time, we also focus on interactions with host cells and local innate immune mechanisms involved in the response to vaginal fungal invasion that are now considered equally important in this case. The presented review describes the most important aspects of the still unknown pathogenicity of Candida associated with vaginal infections.

1. Introduction

The first account of yeast fungus infections probably dates to the 5th century BC. The oldest documented reports indicating a clinical link between candidiasis and fungi were made in 1839. Since then, Candida albicans has been recognized as the main etiological factor of candidiasis and other diseases of the mucous membrane [1].
In the period between the discovery of fungi by the ancient Greeks to modern times, the view on the pathogenicity of these microorganisms has changed. It is now known that they are generally not pathogenic for people with a well-functioning immune system. However, in specific clinical situations they may become an etiological factor in severe, life-threatening infections [2]. It is worth noting that the incidence of infections caused by these microorganisms has been systematically increasing around the world, and mortality can reach 60–70% for some groups of patients [2,3,4]. All this makes fungal infections not only an epidemiological problem but a social one as well.

2. Overview of Candida spp.

2.1. Risk Factors Associated with Superficial and Invasive Candida Infections

Colonizing mucous membranes, mainly the oral cavity, intestines, vagina, and skin, fungi of the genus Candida are part of the human microbiota. As commensals, they do not cause infections in healthy people. They are considered opportunistic microorganisms which cause infections only in specific clinical situations and in the presence of favorable conditions. They mainly pose a threat to immunocompromised persons or patients hospitalized for a long time. People in these risk groups suffer from mucosal infections caused by switching commensal yeast-like fungi to pathogenic ones. Importantly, the risk factors described in detail below also create a predisposition to candidemia and other invasive candidiasis [5].
Factors predisposing to infection with fungi of the genus Candida can be classified into immunological and non-immunological [4]. The first group includes, among others, HIV infection. As the disease progresses, more than 90% of patients suffer from superficial fungal infections affecting mainly the oropharynx, primarily related to low levels of CD4+ lymphocytes, reduced activity of NK cells, and loss of T helper cells. The dominating species in this group of patients is C. albicans, but infections may also be caused by Candida tropicalis, Candida krusei, or Candida parapsilosis [4].
Immunosuppressive therapy, used, for example, in transplant patients, reduces the natural immune response, which makes the body more susceptible to all kinds of fungal infections, especially with C. albicans. The same is true for neoplastic diseases. The disease itself and the therapy used often lead to immunosuppression and disruption of the mechanisms of both humoral and cellular immune response [4]. The incidence of candidiasis among cancer patients treated in hospitals is higher compared to patients hospitalized for other causes [6].
A lowered level of leukocytes in the blood is an important risk factor, especially for patients with haematological disorders. It may result from the ongoing disease process, as well as from the therapy used (chemotherapy or antimicrobial treatment). It is worth adding that patients with chemotherapy-induced neutropenia are often in a serious condition that is additionally accompanied by the presence of other factors conducive to fungal infections (e.g., the use of broad-spectrum antibiotics and vascular catheters) [6].
Regarding non-immunological factors, it is worth mentioning disorders in the quantitative and qualitative composition of the microbiota, which promote the excessive multiplication of fungi. Diabetes and the associated high glycemia promote the colonization of fungi. In people with diabetes, much higher colonization of the oral mucosa with Candida fungi has been observed compared to the healthy population [3,4]. Reduced saliva flow or impaired neutrophil activity seem to be major factors here [3]. Hormonal disorders, especially in pregnant women, are also worth mentioning. Drugs that reduce the secretion of gastric juice or insufficient secretion of digestive enzymes promote the multiplication of fungi in the digestive tract. Inadequate diet, alcohol, lack of vitamins (especially vitamin A, vitamins B6, B12, and C) and microelements (selenium, zinc, iron), smoking, aging of the body, or chronic stress favor these types of infections [4,7]. Not without significance are also past surgeries, especially in the abdominal cavity or parenteral nutrition [8]. Patients with recurrent intestinal perforation or acute necrotizing pancreatitis have a higher risk of candidaemia [6]. The same applies to total parenteral nutrition—it increases the risk of candidiasis almost 4-fold [8]. The presence of a vascular catheter and its colonization may constitute the port of entry for the fungi to the bloodstream [6]. Past surgery, parenteral nutrition, or the use of endovascular catheters are all factors increasing the risk of (mainly systemic) infections [8].
Fungal infections often occur in extreme age groups: newborns, especially premature babies with low birth weight, and the elderly. Undoubtedly, the above is related to the functioning of the immune system—newborns do not have well-developed specific and nonspecific immune responses. In the case of older people, due to age, the immune system is no longer as efficient [9,10]. There may be additional factors in both groups. In the case of newborns, an important factor is the absence of microbiota in the gastrointestinal tract. A disruption in the process of acquiring a microbiota can lead to colonization by pathogenic microorganisms, including fungi. Hospitalization at an ICU, the use of vascular catheters, parenteral nutrition, and antibiotic therapy make them a group with a higher risk of infection [6,9]. It is worth adding that the risk of infection is higher for newborns with bodyweight of less than 1000 g than for newborns weighing more than 2500 g [6]. Similarly, in the case of the elderly, the use of immunosuppressive therapy, broad-spectrum antimicrobial drugs, or comorbidities such as diabetes often increase the risk of infections, especially in patients over 65 years of age [11].
The ability of fungi of the genus Candida, especially C. albicans, to colonize or infect various sites (tissues) in the human body depends on many pathogenic factors of these microorganisms. Some of them, especially those important in the context of inducing vulvovaginitis, will be discussed in more detail later in the paper. It may be worth emphasizing. However, morphological changes and phenotypic switching, expression of a number of adhesins and invasins on the cell surface, the ability to form a biofilm, or the secretion of hydrolytic enzymes are considered the most important pathogenicity factors of these microorganisms. They allow colonization, adhesion, invasion, and damage to the host tissues. Their ability to adapt to the changing pH of an environment, as well as efficient systems for obtaining nutrients [12,13], are also of great significance.

2.2. Most Commonly Isolated Species

C. albicans is the species most often responsible for infections. However, it is worth noting that in recent years there has been an increased incidence of isolation of species other than C. albicans: Candida glabrata, C. tropicalis, C. parapsilosis, Candida dubliniensis, Candida guilliermondii, C. krusei, or Candida kefyr [2,14]. Epidemiological data confirm this trend worldwide [14]. Recent years witnessed a particular increase in the incidence of candidiasis caused by rarely isolated C. krusei or C. guilliermondii [15].
The suspected causes of the change in the epidemiology of fungal infections are the frequent use of compounds with antifungal activity, both in the prevention and empirical treatment of infections. Abuse or improper use of antifungal drugs are most likely causes of reduced susceptibility or even resistance of fungi to antifungal drugs. Increasingly, species other than C. albicans are responsible for infections, and, importantly, they demonstrate a reduced susceptibility to antifungal drugs [15,16]. When analyzing the frequency of isolation of yeast-like fungi from various clinical materials, Taei et al. showed that among NCAC (Non-Candida albicans Candida) species, C. glabrata was most often isolated (it accounted for 76% of all NCACs). The next most isolated were C. krusei (6.6%), C. kefyr (5.7%), C. parapsilosis (4.9%), and C. tropicalis (2.4%). The least common (0.8%) were C. dubliniensis, C. guilliermondii, and Candida famata. C. albicans accounted for 38.5% of all isolated fungi of the genus Candida [14]. According to the authors of the aforementioned paper, the increase in the frequency of NCAC isolation is a result of better laboratory diagnostics as well as previous exposure to polyenes and azoles or of reduced immunity, which is often related to the therapy used, e.g., cytostatics, in transplant or cancer patients. Diabetes was a common factor conducive to NCAC infections [14]. Research by Das et al. showed a similar relationship. Of the 112 Candida fungi isolated from vaginal swabs, 58% were non-C. albicans species. Among them, C. glabrata (20%), C. tropicalis (19%), and C. parapsilosis (9%) were isolated most often. C. albicans was isolated in 42% of cases [17]. Despite C. albicans being the most commonly isolated, an increasing share of NCAC species and their dominance in complicated vulvovaginitis was observed. The authors explain the above primarily by prolonged antifungal treatment, diabetes, older age, and poor hygienic conditions. NCAC species were also shown to have a higher resistance to antifungal drugs compared to C. albicans [17]. Liu et al., who focused on the assessment of risk factors for NCAC candidiasis, showed that C. albicans, C. tropicalis, C. glabrata, and C. parapsilosis were most often isolated. The above species accounted for more than 96% of all isolated fungi of the genus Candida. NCAC and C. albicans were isolated in 53.5% and 46.5% of candidiasis cases, respectively. Among NCACs, C. tropicalis was most isolated, primarily from patients with haematological tumors. The authors have demonstrated a higher resistance among NCAC species, particularly of C. tropicalis isolates [18].
When discussing species other than C. albicans, Candia auris is worth mentioning. First isolated in Japan in 2009 from a patient with otitis, it has become a causative agent of invasive infections around the world. It is characterized by ease of spreading, resistance to antifungal agents and disinfectants, a wide range of pathogenic factors, and the fact that it causes severe infections with a high, estimated at even 72%, mortality rate [19,20,21]. Most often, it causes infections in patients who are artificially ventilated, hospitalized in the intensive care unit, catheterized, HIV-infected, diabetic and immunosuppressed. Other factors predisposing to C. auris infections include parenteral nutrition, previous surgery, or long-term use of antimicrobials [19,20,22]. C. auris is currently a global threat, causing severe epidemic outbreaks of invasive infections most often associated with medical care [21].

2.3. Infections Caused by Fungi of the Genus Candida

Among the infections caused by Candida spp. fungi, one can distinguish surface infections and systemic infections [12,19,20,23]. Surface infections are not generally life-threatening [12]. Among them, one can mention infections of the skin and nails, mucous membrane of the mouth, throat, esophagus, intestines, and vagina [12,24]. Systemic infections, on the other hand, are characterized by a severe course and pose a direct threat to human life. Systemic candidiasis is associated with high mortality, and neutropenia, as well as damage to the gastrointestinal mucosa, are quoted as the most common factors predisposing to this type of infection. Other factors include the use of central venous catheters or antibacterial therapy, most often with broad-spectrum agents [12].
Skin infections are most often surface infections, while infections involving the dermis and subcutaneous layer occur very rarely. The changes most often affect skin folds, e.g., inguinal folds, and often occur in overweight people. Candida spp. may also be the causative agent of paronychia or onychomycosis [23]. Oral candidiasis is mainly caused by C. albicans and most often occurs in people with impaired immune function. The most common risk factors are HIV infection, followed by wearing prostheses and braces, old age, xerostomia, or poor oral hygiene [12,23]. Esophageal candidiasis is most often caused by C. albicans and occurs primarily in people with an impaired immune system or with concomitant diseases, e.g., diabetes. Often, it is manifested by odynophagia and dysphagia, but it can also be completely asymptomatic [23]. Intestinal mycosis is most often superficial, but it can also occur with intestinal perforation. Fungal infections of the intestines are most often associated with inflammatory bowel disease [23].
According to statistical data, about 75% of women have experienced vulvovaginal candidiasis (VVC) at least once in their lifetime, and in about 5–8% of them, it has a recurrent character (occurs at least four times per year) [12]. The pathomechanism of VVC and the pathogenicity of Candida spp. fungi associated with vaginal infections will be discussed further in the paper.
Invasive infections are most commonly caused by C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. kefyr [23]. These fungi are some of the most common etiological factors of invasive infections, primarily in patients in intensive care units [25]. The entry of fungi into the bloodstream may result in the spread of fungi into tissues and organs [24]. It can cause, among others, meningitis, peritonitis, and abdominal infections, endocarditis, or infections affecting the patient’s bones and joints [23]. The above-mentioned risk factors for invasive infections also include old age, parenteral nutrition, cancer, and immunosuppressive treatment [25].
Candida spp. fungi are also causative agents of infections associated with a foreign element (biomaterial) introduced into the human body. In this context, the adhesive properties of fungi and their ability to form biofilm are important. The possibility of fungal colonization in hip replacements, vascular catheters, urinary catheters, endotracheal tubes, dental implants, artificial valves, pacemakers, or even contact lenses has been demonstrated [26,27]. Infections that occur with the formation of biofilm often have a chronic, recurrent character and are characterized by a high mortality rate of more than 40% [27]. Biofilm plays an important role, protecting the fungal cells against the immune mechanisms of the human body as well as against antifungal agents. The therapeutic options for infections with biofilm-forming organisms are extremely limited [27]. The formation of biofilm structures on the biomaterial may result in blood infection or systemic infection of tissues and organs [28].

3. Vulvovaginal Candidiasis

As noted earlier, vulvovaginal candidiasis affects many women around the world. After bacterial infections, it is the second most common type of vaginal infection [12,29,30,31]. The clinical picture may vary, but most often, its symptoms include itching of the vagina and vulva, soreness, burning, and abnormal vaginal discharge. Other symptoms may include difficulty urinating and pain during sexual intercourse [29]. Data in the literature show that the incidence of this type of infection partially depends on the age of the woman, which also determines sexual maturity, hormonal activity, and the state of the vaginal microbiota [29,30,32]. The most common factors predisposing to VVC are pregnancy, the luteal phase of the menstrual cycle, the use of broad-spectrum antibiotics, the use of intrauterine devices, estrogen replacement therapy, immunosuppression, diabetes, or mechanical factors, e.g., the use of tight, synthetic underwear [31,33,34].
Research by Zeng et al. showed that women under 40 years of age had a higher risk of vaginal mycosis than older women [29]. It is also rarely diagnosed in patients before puberty [33]. Vulvovaginal candidiasis occurs primarily in young women of childbearing age and rarely in premenopausal women [30]. Almost 55% of women before the age of 25 will experience a VVC episode [33]. Sexual activity and physiological and tissue changes that are caused by reproductive hormones that occur in women during this period of life, seem to be important here. They increase susceptibility to Candida spp. infection [29].
To a large extent, the above has to do with the activity of sex hormones during the reproductive period and with low levels of estrogen and progesterone during menopause. During reproductive age, high levels of estrogen induce the hypertrophy of the vaginal mucosal epithelium as well as the secretion of glycogen by vaginal epithelial cells. Its fermentation to lactic acid by Lactobacillus, the main component of the vaginal microbiota, leads to a significant decrease in pH, which prevents the development of other microorganisms. In addition to ensuring proper vaginal pH, Lactobacillus bacteria, primarily Lactobacilluis crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus iners, produce a number of substances, such as hydrogen peroxide or bacteriocins, which inhibit the multiplication of other microorganisms. They also compete for nutrients and receptors on vaginal epithelial cells with other microorganisms [30,32]. In menopausal women, a drop in estrogen levels and vaginal atrophy occurs, leading to a decrease in glycogen levels in vaginal epithelial cells and a neutral pH [32,34]. As Hoffmann points out, vulvovaginal candidiasis often occurs at lower pH values of vaginal secretions, which is the case for healthy women of childbearing age. Low hormone levels and vaginal atrophy are associated with a much lower risk of VVC in postmenopausal women [34]. It is generally accepted that a decrease in the level of lactobacilli or their complete absence predisposes women to VVC [30]. However, in his 2010 paper, McCelland showed that colonization of the vagina with Lactobacillus increases the risk of VVC by a factor of four [30,35]. Additionally, Ceccarani et al. showed that the vaginal microbiota of healthy women was dominated by L. crispatus. In a state of disease, the abundance of this species decreased while the number of L. iners increased significantly. The same relationship was also demonstrated by the mentioned authors for VVC. Additionally, high levels of glucose in the vagina of women with VVC were shown. On the one hand, glucose is a nutrient for Candida spp. However, on the other hand it promotes the expression of binding molecules in vaginal epithelial cells, thus increasing the adhesion of Candida. As the authors point out, high levels of glucose in the vagina may be associated with a reduction in the abundance of L. crispatus [36].
Data in the literature show that vaginal colonization with Candida spp. is greater in pregnant women (especially in the second and third trimester of pregnancy) than in non-pregnant women. The above state of affairs is most often explained by reduced cell-mediated immunity, high estrogen levels, and high glycogen levels, which promotes colonization with Candida spp. [37,38].
The diagnosis of vulvovaginal candidiasis is based on symptomatic vulvovaginitis with simultaneous isolation of Candida spp. from the clinical material (or from a vaginal swab) in the absence of any other etiology [30,39]. As mentioned earlier, about 75% of women will experience vulvovaginal candidiasis (VVC) at least once in their lives, and in about 5–8% of them, it will be recurrent (at least four VVC per year) [12]. Recurrent vulvovaginal candidiasis affects nearly 138 million women annually [39].
In the vast majority of cases, the etiological factor of VVC is C. albicans. However, more and more frequently, the causative agents are species other than C. albicans, e.g., C. glabrata, C. parapsilosis, C. tropicalis or C. krusei [39]. An increase in the isolation of NCAC species in recurrent and complicated VVC was observed [17,39]. It is commonly known that species other than C. albicans are characterized by greater virulence and resistance to antifungal agents, which often leads to therapeutic failures [39].

5. Pathogenicity of Fungi of the Genus Candida spp. Associated with Vaginal Infections—Host Immune Response

The role and significance of specific virulence factors of Candida are not the only factors that have remained unknown until today. After many years of intensive research on the immune mechanisms involved in the pathogenesis of VVC, there is still more to be discovered than is known. Nevertheless, especially in the last few years, several factors, and mechanisms potentially crucial for the development of fungal infection in the vagina have been identified, related to the host’s response to the presence of Candida.
It turned out relatively quickly that the acquired cellular or humoral immune response plays no role in VVC. Similarly, searches for the potentially protective role of innate immune components, such as macrophage or dendritic cell activity, did not reveal their effect on the vagina [43,80,81,82]. What has now been proven, vaginal epithelial cells (VEC) should be considered the first line of the host’s defense. On their surface, there are so-called PRRs (pattern recognition receptors) responsible for the recognition of Candida. Many authors emphasize that it is VEC that has the ability to distinguish and determine the fungi present on the vaginal mucosa as commensal or as pathogenic [43,80,81,83,84]. The most frequently cited hypothesis indicates the fungistatic action of epithelial cells, significantly limiting the development of infection and promoting the state of asymptomatic commensalism. The mechanisms underlying this phenomenon remain unknown. Annexin A1 can probably play a role here. The above way of VEC response predominates in women who are not susceptible to fungal infection, most often without a history of VVC/RVVC, in whom there is no further activation of the immune system [80,82]. This possibility is presented in Figure 1.
Figure 1. Recognition of Candida blastospores by VEC (vaginal epithelial cells) in women not susceptible to VVC (vulvovaginal candidiasis). PRRs (pattern recognition receptors) classify blastospores as commensals—no immunological reaction is provided.
In women susceptible to infection (Figure 2), PRRs on the VEC surface recognize the components of the Candida cell wall and, in response, begin the production of a number of pro-inflammatory cytokines and alarmins, which in turn have a chemotactic effect on the PMN (polymorphonuclear) neutrophils located in the tissue stroma. Strong infiltration of vaginal tissue by PMN has been repeatedly shown in women manifesting clinical symptoms of VVC. It has been possible to clearly demonstrate that it is the immune response associated with PMN that is the cause of the symptoms of infection. In this way, one of the strongest pieces of evidence for the immunopathological origin of vulvovaginal candidiasis was provided, with VVC being an infection resulting not so much from the presence of the pathogen but the massive inflammatory response of the host organism and the resulting damage [43,80,81,84,85].
Figure 2. Recognition of Candida blastospores by VEC (vaginal epithelial cells) in women susceptible to VVC (vulvovaginal candidiasis). PRRs (pattern recognition receptors) classify blastospores as pathogens—production of proinflammatory cytokines, chemokines and alarmins is started. PMNs (polimorfonuclears) infiltrate VECs but are unable to kill Candida or directly damaging tissue. This state relates to clinical symptoms of VVC (detailed mechanism still unknown).
PMN cells migrating to the site of infection in response to the signals sent are not capable of effectively reducing or eliminating fungal cells. It has also been confirmed that they are not responsible for the damage to vaginal tissue associated with the infection that is observed during VVC [80,81]. Therefore, it is clear that the mechanism described above cannot be the only one underlying the infection in question. The virulence factors of fungi of the genus Candida and the resulting inflammatory response are also crucial. The most important in the immune context now seems to be phenotypic switching and hyphae growth. One of the most important factors associated with hyphae and identified recently is candidalysin, a toxin with lytic activity encoded by the ECE1 (extent of cell elongation 1) gene. It works in two ways—on the one hand, it has the ability to activate the NLRP3 inflammasome; on the other hand, it causes damage to vaginal tissue directly [80,81,85]. NLRP3 is an intracellular receptor complex that performs a protective function in most types of candidiasis. In the vagina, however, after its oligomerization, caspase-1 and a further signal path are activated, because of which IL-1β, the main effector of inflammation, as well as alarmin S100A8, are produced and released. As a result, large amounts of many different pro-inflammatory cytokines, chemokines, and alarmins are released, which are also responsible for the recruitment of PMN to the site of infection [43,60,80,81,84,85,86]. Since PMNs are not able to effectively kill fungal cells in this case, the next step is their death and granular release, which, in positive feedback, causes further cytokine release and chemotaxis of subsequent PMNs, intensifying the inflammation [80,81]. In addition to candidalysin, other hyphae-related factors are also indicated that could act similarly, such as some Sap (although their role remains controversial), Als, lipases, or SAA3, activating NLRP3 [60,80,81,85,86].
Candidalysin also causes direct damage to the VEC—it is now considered a key factor responsible for this effect. Experiments were carried out, which proved that the mere presence of hyphae (in the absence of toxin-producing ability) does not cause damage to the vaginal tissues during Candida infection. Therefore, it is highly probable that this peptide is the main factor behind the invasiveness of the hyphae form of yeast-like fungi and their ability to penetrate deep into the tissues [80,81,84]. In addition to its obvious clinical significance, VEC damage is also associated with yet another relatively recently discovered factor. It has been proven that VEC damage involves the release of, among others, heparan sulfate (HS). Observations confirmed that HS might be responsible for the so-called neutrophil anergy or inability to produce an immune response to an immunogen. The antifungal activity of PMN is conditioned by the specific recognition of fungal cells, which occurs through Mac1 present on neutrophils, binding to Pra1p (pH-regulated antigen 1 protein) in Candida. It is worth mentioning that this protein is present in a much higher density in hyphae cells than in blastospores. In other candidiasis types, Mac1 activation promotes the killing of fungal cells by creating so-called NETs (neutrophil extracellular traps). In VVC, this phenomenon does not occur, and it has been proven that HS acts as a competitive ligand for Mac1, blocking the target Pra1p binding point, which prevents the killing of Candida and is most likely responsible for the anergy phenomenon. Recent reports also focus on the role of estrogens in the development of infection. Their large amount also causes an increase in the release of HS and thus may contribute to additional impairment of cidal functions of PMNs. A possible role of estrogens in the direct activation of the NLRP3 inflammasome is also indicated [80,81,86]. The described hypothesis is presented in Figure 3.
Figure 3. Hypothetical explanation of processes underlying tissue damage and clinical symptoms during VVC (vulvovaginal candidiasis) associated with production and release of candidalysin.
The above interactions are only the first step in identifying key immune factors relevant to VVC immunopathogenesis. Researchers are currently interested in so many other immune components and mechanisms potentially involved in the host response to the presence of Candida on the vaginal mucosa that an attempt at listing them is far beyond the scope of this paper. However, it is worth emphasizing that there is no longer any doubt that for the development of symptomatic vaginal candidiasis, the action of both components associated with the innate immune response and the activity of a number of interrelated virulence factors of yeast-like fungi is necessary.

6. Summary

The above-listed factors and mechanisms are not the only ones currently being investigated in the context of VVC pathogenesis. In addition to the enormous complexity of molecular and immunological processes involved in the described phenomena and the difficulties associated with determining the specific functions of individual components, both related to Candida and the host’s immune system, problems also arise with ensuring reliable experiments in the research laboratory. The tools most commonly used to assess fungus-host interactions are mouse models and, less frequently, rat models. Many of the discussed mechanisms were observed in an animal model and then confirmed in studies using clinical material taken from female volunteers. However, there are many more laboratory observations, mainly regarding mice, waiting to be verified in human studies. However, the proper and reliable design of such studies continues to be difficult. A similar situation applies to experiments using reconstituted vaginal epithelial cells. Despite the above, recent years have undoubtedly brought many milestones in understanding the pathomechanism of the development of VVC. Although there is still a long way to go to understand the development of VVC fully, the identified factors and mechanisms are already the goal of new antifungal therapies under development, aimed both at fighting an active infection and preventing its development.

Author Contributions

P.C. and J.N. wrote the manuscript; G.G. reviewed the manuscript and managed the supervision. All authors have read and agreed to the published version of the manuscript.

Funding

This research was financially supported by the Ministry of Health subvention according to number of STM.A130.20.102 from the IT Simple system of Wroclaw Medical University as well as financed from the funds granted by the Ministry of Education and Science in the „Regional Initiative of Excellence” programme for the years 2019–2022, project number 016/RID/2018/19, the amount of funding 9 354 023,74 PLN.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Yang, B.; Rao, R. Emerging Pathogens of the Candida Species. Intech Open Sci. 2012, 1, 3–18. [Google Scholar] [CrossRef] [Green Version]
  2. Singh, D.K.; Tóth, R.; Gácser, A. Mechanisms of Pathogenic Candida Species to Evade the Host Complement Attack. Front. Cell. Infect. Microbiol. 2020, 10, 94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Rodrigues, C.F.; Rodrigues, M.E.; Henriques, M. Candida sp. Infections in patients with diabetes mellitus. J. Clin. Med. 2019, 8, 76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Singh, S.; Fatima, Z.; Hameed, S. Predisposing factors endorsing Candida infections. Infez. Med. 2015, 23, 211–223. [Google Scholar] [PubMed]
  5. Wróblewska, M.; Sulik-Tyszka, B. Candida auris—Epidemiology and laboratory diagnostics of infections. Diagnostyka Lab. 2017, 53, 235–240. [Google Scholar] [CrossRef]
  6. Alberto Cortés, J.; Fernanda Corrales, I. Invasive Candidiasis: Epidemiology and Risk Factors. In Fungal Infection; IntechOpen: London, UK, 2018; pp. 33–46. [Google Scholar]
  7. Vila, T.; Sultan, A.S.; Montelongo-Jauregui, D.; Jabra-Rizk, M.A. Oral candidiasis: A disease of opportunity. J. Fungi 2020, 6, 15. [Google Scholar] [CrossRef] [Green Version]
  8. Sikora, M. Czynniki wirulencji grzybów z rodzaju candida istotne w patogenezie zakażeń występujących u pacjentów żywionych pozajelitowo. Postep. Mikrobiol. 2015, 3, 224–234. [Google Scholar]
  9. Arsenault, A.B.; Bliss, J.M. Neonatal Candidiasis: New Insights into an Old Problem at a Unique Host-Pathogen Interface. Curr. Fungal Infect. Rep. 2015, 9, 246–252. [Google Scholar] [CrossRef] [Green Version]
  10. Flevari, A.; Theodorakopoulou, M.; Velegraki, A.; Armaganidis, A.; Dimopoulos, G. Treatment of invasive candidiasis in the elderly: A review. Clin. Interv. Aging 2013, 8, 1199–1208. [Google Scholar] [CrossRef] [Green Version]
  11. Dekkers, B.G.J.; Veringa, A.; Marriott, D.J.E.; Boonstra, J.M.; van der Elst, K.C.M.; Doukas, F.F.; McLachlan, A.J.; Alffenaar, J.W.C. Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. Drugs Aging 2018, 35, 781–789. [Google Scholar] [CrossRef] [Green Version]
  12. Mayer, F.L.; Wilson, D.; Hube, B. Candida albicans pathogenicity mechanisms. Virulence 2013, 4, 119–128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Lopes, J.P.; Lionakis, M.S. Pathogenesis and virulence of Candida albicans. Virulence 2022, 13, 89–121. [Google Scholar] [CrossRef] [PubMed]
  14. Taei, M.; Chadeganipour, M.; Mohammadi, R. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples; a combination of various molecular techniques for identification of etiologic agents. BMC Res. Notes 2019, 12, 779. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Aydemir, Ö.; Demiray, T.; Köroğlu, M.; Aydemir, Y.; Altındiş, M. Emerge of non-albicans Candida species; evaluation of Candida species and antifungal susceptibilities according to years. Biomed. Res. 2017, 28, 2820–2825. [Google Scholar]
  16. Lindberg, E.; Hammarström, H.; Ataollahy, N.; Kondori, N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Sci. Rep. 2019, 9, 12–17. [Google Scholar] [CrossRef] [Green Version]
  17. Das, K.H.; Mangayarkarasi, V.; Sen, M. Antifungal resistant in non-albicans candida species are emerging as a threat to antenatal women with vulvovaginal candidiasis. Biomed. Pharmacol. J. 2019, 12, 1369–1378. [Google Scholar] [CrossRef]
  18. Liu, F.; Zhong, L.; Zhou, F.; Zheng, C.; Zhang, K.; Cai, J.; Zhou, H.; Tang, K.; Dong, Z.; Cui, W.; et al. Clinical features, strain distribution, antifungal resistance and prognosis of patients with non-albicans candidemia: A retrospective observational study. Infect. Drug Resist. 2021, 14, 3233–3246. [Google Scholar] [CrossRef]
  19. Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms 2021, 9, 807. [Google Scholar] [CrossRef]
  20. Grondalska, D.; Kmieciak, W. Candida auris—Nowy patogen grzybiczy. Post. Mikrobiol 2019, 191, E865. [Google Scholar]
  21. Garcia-Bustos, V.; Ruiz-Saurí, A.; Ruiz-Gaitán, A.; Sigona-Giangreco, I.A.; Cabañero-Navalon, M.D.; Sabalza-Baztán, O.; Salavert-Lletí, M.; Tormo, M.Á.; Pemán, J. Characterization of the Differential Pathogenicity of Candida auris in a Galleria mellonella Infection Model. Microbiol. Spectr. 2021, 9, e0001321. [Google Scholar] [CrossRef]
  22. Keighley, C.; Garnham, K.; Harch, S.A.J.; Robertson, M.; Chaw, K.; Teng, J.C.; Chen, S.C.A. Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory. Curr. Fungal Infect. Rep. 2021, 15, 116–126. [Google Scholar] [CrossRef] [PubMed]
  23. Talapko, J.; Juzbašić, M.; Matijević, T.; Pustijanac, E.; Bekić, S.; Kotris, I.; Škrlec, I. Candida albicans-the virulence factors and clinical manifestations of infection. J. Fungi 2021, 7, 79. [Google Scholar] [CrossRef] [PubMed]
  24. Staniszewska, M.; Bondaryk, M.; Kowalska, M.; Magda, U.; Łuka, M.; Ochal, Z.; Kurzątkowski, W. Pathogenesis and treatment of fungal infections by Candida spp. [Patogeneza i leczenie zakażeń Candida spp.]. Postep. Mikrobiol. 2014, 53, 229–240. [Google Scholar]
  25. Khan, F.; Bamunuarachchi, N.I.; Pham, D.T.N.; Tabassum, N.; Khan, M.S.A.; Kim, Y.M. Mixed biofilms of pathogenic Candida-bacteria: Regulation mechanisms and treatment strategies. Crit. Rev. Microbiol. 2021, 45, 699–727. [Google Scholar] [CrossRef] [PubMed]
  26. Ramage, G.; Martínez, J.P.; López-Ribot, J.L. Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res. 2006, 6, 979–986. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Vera-González, N.; Shukla, A. Advances in Biomaterials for the Prevention and Disruption of Candida Biofilms. Front. Microbiol. 2020, 11, 2251. [Google Scholar] [CrossRef]
  28. Peng, Z.; Tang, J. Intestinal Infection of Candida albicans: Preventing the Formation of Biofilm by C. albicans and Protecting the Intestinal Epithelial Barrier. Front. Microbiol. 2022, 12, 783010. [Google Scholar] [CrossRef]
  29. Zeng, X.; Zhang, Y.; Zhang, T.; Xue, Y.; Xu, H.; An, R. Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi’an: A Cross-Sectional Study. Biomed Res. Int. 2018, 2018, 9703754. [Google Scholar] [CrossRef] [Green Version]
  30. Achkar, J.M.; Fries, B.C. Candida infections of the genitourinary tract. Clin. Microbiol. Rev. 2010, 23, 253–273. [Google Scholar] [CrossRef] [Green Version]
  31. Aniebue, U.U.; Nwankwo, T.O.; Nwafor, M.I. Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. Niger. J. Clin. Pract. 2018, 21, 1017–1022. [Google Scholar] [CrossRef]
  32. Auriemma, R.S.; Scairati, R.; del Vecchio, G.; Liccardi, A.; Verde, N.; Pirchio, R.; Pivonello, R.; Ercolini, D.; Colao, A. The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life. Front. Cell. Infect. Microbiol. 2021, 11, 613. [Google Scholar] [CrossRef] [PubMed]
  33. Lema, V.M. Recurrent Vulvo-Vaginal Candidiasis: Diagnostic and Management Challenges in a Developing Country Context. Obstet. Gynecol. Int. J. 2017, 7, 00260. [Google Scholar] [CrossRef]
  34. Hoffmann, J.N.; You, H.M.; Hedberg, E.C.; Jordan, J.A.; McClintock, M.K. Prevalence of bacterial vaginosis and Candida among postmenopausal women in the United States. J. Gerontol. Ser. B Psychol. Sci. Soc. Sci. 2014, 69, S205–S214. [Google Scholar] [CrossRef] [PubMed]
  35. McClelland, R.S.; Richardson, B.A.; Hassan, W.M.; Graham, S.M.; Kiarie, J.; Baeten, J.M.; Mandaliya, K.; Jaoko, W.; Ndinya-Achola, J.O.; Holmes, K.K. Prospective study of vaginal bacteria flora and other risk factors for vulvovaginal candidiasis. J. Infect. Dis. 2009, 199, 1883–1890. [Google Scholar] [CrossRef] [Green Version]
  36. Ceccarani, C.; Foschi, C.; Parolin, C.; D’Antuono, A.; Gaspari, V.; Consolandi, C.; Laghi, L.; Camboni, T.; Vitali, B.; Severgnini, M.; et al. Diversity of vaginal microbiome and metabolome during genital infections. Sci. Rep. 2019, 9, 14095. [Google Scholar] [CrossRef] [Green Version]
  37. Konadu, D.G.; Owusu-Ofori, A.; Yidana, Z.; Boadu, F.; Iddrisu, L.F.; Adu-Gyasi, D.; Dosoo, D.; Awuley, R.L.; Owusu-Agyei, S.; Asante, K.P. Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. BMC Pregnancy Childbirth 2019, 19, 1–10. [Google Scholar] [CrossRef]
  38. Ang, X.Y.; Mageswaran, U.M.; Chung, Y.L.F.; Lee, B.K.; Azhar, S.N.A.; Roslan, N.S.; Saufian, I.F.B.; Mustaffa, N.S.; Kalam, E.M.; Ibrahim, A.F.; et al. Probiotics Reduce Vaginal Candidiasis in Pregnant Women via Modulating Abundance of Candida and Lactobacillus in Vaginal and Cervicovaginal Regions. Microorganisms 2022, 10, 285. [Google Scholar] [CrossRef]
  39. Żyrek, D.; Wajda, A.; Czechowicz, P.; Nowicka, J.; Jaśkiewicz, M.; Neubauer, D.; Kamysz, W. The antimicrobial activity of omiganan alone and in combination against candida isolated from vulvovaginal candidiasis and bloodstream infections. Antibiotics 2021, 10, 1001. [Google Scholar] [CrossRef]
  40. Swidsinski, A.; Guschin, A.; Tang, Q.; Dörffel, Y.; Verstraelen, H.; Tertychnyy, A.; Khayrullina, G.; Luo, X.; Sobel, J.D.; Jiang, X. Vulvovaginal candidiasis: Histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am. J. Obstet. Gynecol. 2019, 220, e1–e91. [Google Scholar] [CrossRef] [Green Version]
  41. Rodríguez-Cerdeira, C.; Gregorio, M.C.; Molares-Vila, A.; López-Barcenas, A.; Fabbrocini, G.; Bardhi, B.; Sinani, A.; Sánchez-Blanco, E.; Arenas-Guzmán, R.; Hernandez-Castro, R. Biofilms and vulvovaginal candidiasis. Colloids Surf. B Biointerfaces 2019, 174, 110–125. [Google Scholar] [CrossRef]
  42. Silva, S.; Negri, M.; Henriques, M.; Oliveira, R.; Williams, D.W.; Azeredo, J. Adherence and biofilm formation of non-Candida albicans Candida species. Trends Microbiol. 2011, 19, 241–247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Peters, B.M.; Yano, J.; Noverr, M.C.; Fidel, P.L. Candida Vaginitis: When Opportunism Knocks, the Host Responds. PLoS Pathog. 2014, 10, e1003965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Nobile, C.J.; Johnson, A.D. Candida albicans Biofilms and Human Disease. Annu. Rev. Microbiol. 2015, 69, 71–92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Hacioglu, M.; Guzel, C.B.; Savage, P.B.; Seher Birteksoz Tan, A. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. Isolated from vulvovaginal candidiasis. Med. Mycol. 2019, 57, 291–299. [Google Scholar] [CrossRef] [PubMed]
  46. Tulasidas, S.; Rao, P.; Bhat, S.; Manipura, R. A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections. Infect. Drug Resist. 2018, 11, 2443–2448. [Google Scholar] [CrossRef] [Green Version]
  47. Gonçalves, B.; Ferreira, C.; Alves, C.T.; Henriques, M.; Azeredo, J.; Silva, S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016, 42, 905–927. [Google Scholar] [CrossRef] [Green Version]
  48. Zhu, W.; Filler, S.G. Interactions of Candida albicans with epithelial cells. Cell. Microbiol. 2010, 12, 273–282. [Google Scholar] [CrossRef] [Green Version]
  49. Paiva, L.C.F.; Vidigal, P.G.; Donatti, L.; Svidzinski, T.I.E.; Consolaro, M.E.L. Assessment of in vitro biofilm formation by Candida species isolates from vulvovaginal candidiasis and ultrastructural characteristics. Micron 2012, 43, 497–502. [Google Scholar] [CrossRef]
  50. Silva, S.; Negri, M.; Henriques, M.; Oliveira, R.; Williams, D.W.; Azeredo, J. Candida glabrata, Candida parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol. Rev. 2012, 36, 288–305. [Google Scholar] [CrossRef] [Green Version]
  51. Ielasi, F.S.; Decanniere, K.; Willaert, R.G. The epithelial adhesin 1 (Epa1p) from the human-pathogenic yeast Candida glabrata: Structural and functional study of the carbohydrate-binding domain. Acta Crystallogr. Sect. D Biol. Crystallogr. 2012, 68, 210–217. [Google Scholar] [CrossRef]
  52. Staniszewska, M.; Bondaryk, M.; Siennicka, K.; Piłat, J.; Schaller, M.; Kurza̧tkowski, W. Role of aspartic proteinases in Candida albicans virulence. Part I. Substrate specificity of Aspartic proteinases and Candida albicans pathogenesis (Postepy Mikrobiologii (2012) (131)). Postep. Mikrobiol. 2012, 51, 236. [Google Scholar]
  53. Vylkova, S.; Lorenz, M.C. Encounters with Mammalian Cells: Survival Strategies of Candida Species. In Candida and Candidiasis, 2nd. ed.; Calderone, R.A., Clancy, C.J., Eds.; American Society of Microbiology: Washington, DC, USA, 2012; pp. 261–282. [Google Scholar]
  54. Sikora, M.; Dabkowska, M.; Swoboda-Kopec, E.; Jarzynka, S.; Netsvyetayeva, I.; Jaworska-Zaremba, M.; Pertkiewicz, M.; Mlynarczyk, G. Differences in proteolytic activity and gene profiles of fungal strains isolated from the total parenteral nutrition patients. Folia Microbiol. 2011, 56, 143–148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Tellapragada, C.; Eshwara, V.K.; Johar, R.; Shaw, T.; Malik, N.; Bhat, P.V.; Kamath, A.; Mukhopadhyay, C. Antifungal Susceptibility Patterns, In Vitro Production of Virulence Factors, and Evaluation of Diagnostic Modalities for the Speciation of Pathogenic Candida from Blood Stream Infections and Vulvovaginal Candidiasis. J. Pathog. 2014, 2014, 142864. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Sobel, J.D. Vulvovaginal candidosis. Lancet 2007, 369, 1961–1971. [Google Scholar] [CrossRef]
  57. Jafari, M.; Salari, S.; Pakshir, K.; Zomorodian, K. Exoenzyme activity and possibility identification of Candida dubliniensis among Candida albicans species isolated from vaginal candidiasis. Microb. Pathog. 2017, 110, 73–77. [Google Scholar] [CrossRef]
  58. Naglik, J.R.; Rodgers, C.A.; Shirlaw, P.J.; Dobbie, J.L.; Fernandes-Naglik, L.L.; Greenspan, D.; Agabian, N.; Challacombe, S.J. Differential Expression of Candida albicans Secreted Aspartyl Proteinase and Phospholipase B Genes in Humans Correlates with Active Oral and Vaginal Infections. J. Infect. Dis. 2003, 188, 469–479. [Google Scholar] [CrossRef] [Green Version]
  59. Calderone, R.A.; Fonzi, W. A Virulence factors in Candida albicans. TRENDS Microbiol. 2001, 9, 327–335. [Google Scholar] [CrossRef]
  60. Cassone, A. Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects. BJOG Int. J. Obstet. Gynaecol. 2015, 122, 785–794. [Google Scholar] [CrossRef]
  61. Sudbery, P.; Gow, N.; Berman, J. The distinct morphogenic states of Candida albicans. Trends Microbiol. 2004, 12, 317–324. [Google Scholar] [CrossRef]
  62. Moran, G.; Coleman, D.; Sullivan, D. An Introduction to the Medically Important Candida Species. In Candida and Candidiasis, 2nd ed.; Calderone, R.A., Clancy, C.J., Eds.; American Society of Microbiology: Washington, DC, USA, 2012; pp. 11–25. [Google Scholar]
  63. Consolaro, M.E.L.; Albertoni, T.A.; Svidzinski, A.E.; Peralta, R.M.; Svidzinski, T.I.E. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia 2005, 159, 501–507. [Google Scholar] [CrossRef]
  64. Sudbery, P.E. Growth of Candida albicans hyphae. Nat. Rev. Microbiol. 2011, 9, 737–748. [Google Scholar] [CrossRef] [PubMed]
  65. Tang, Y.; Yu, F.; Huang, L.; Hu, Z. The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. J. Clin. Lab. Anal. 2019, 33, e22644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Lastauskienė, E.; Čeputytė, J.; Girkontaitė, I.; Zinkevičienė, A. Phenotypic Switching of Candida guilliermondii is Associated with Pseudohyphae Formation and Antifungal Resistance. Mycopathologia 2015, 179, 205–211. [Google Scholar] [CrossRef] [PubMed]
  67. Harriott, M.M.; Noverr, M.C. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol. 2011, 19, 557–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Silva, S.; Henriques, M.; Martins, A.; Oliveira, R.; Williams, D.; Azeredo, J. Biofilms of non-Candida albicans Candida species: Quantification, structure and matrix composition. Med. Mycol. 2009, 47, 681–689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Harriott, M.M.; Lilly, E.A.; Rodriguez, T.E.; Fidel, P.L.; Noverr, M.C. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 2010, 156, 3635–3644. [Google Scholar] [CrossRef] [Green Version]
  70. Muzny, C.A.; Schwebke, J.R. Biofilms: An underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin. Infect. Dis. 2015, 61, 601–606. [Google Scholar] [CrossRef] [Green Version]
  71. Desai, J.V.; Mitchell, A.P. Candida albicans biofilm development and its genetic controls. Microbiol. Spectr. 2015, 3, 139–148. [Google Scholar] [CrossRef] [Green Version]
  72. McKloud, E.; Delaney, C.; Sherry, L.; Kean, R.; Williams, S.; Metcalfe, R.; Thomas, R.; Richardson, R.; Gerasimidis, K.; Nile, C.J.; et al. Recurrent Vulvovaginal Candidiasis: A Dynamic Interkingdom Biofilm Disease of Candida and Lactobacillus. mSystems 2021, 6, e00622-21. [Google Scholar] [CrossRef]
  73. Thein, Z.M.; Seneviratne, C.J.; Samaranayake, Y.H.; Samaranayake, L.P. Community lifestyle of Candida in mixed biofilms: A mini review. Mycoses 2009, 52, 467–475. [Google Scholar] [CrossRef]
  74. Rodrigues, M.E.; Gomes, F.; Rodrigues, C.F. Candida spp./bacteria mixed biofilms. J. Fungi 2020, 6, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Lohse, M.B.; Gulati, M.; Johnson, A.D.; Nobile, C.J. Development and regulation of single-and multi-species Candida albicans biofilms. Nat. Rev. Microbiol. 2018, 16, 19–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Tomaszewski, J. The statement of polish gynecological society experts on the etiology and treatment of recurrent vulvovaginal candidiasis. Ginekol. Pol. 2011, 82, 869–873. [Google Scholar]
  77. Sherry, L.; Kean, R.; Mckloud, E.; Donnell, L.E.O.; Metcalfe, R.; Jones, B.L. Biofilms formed by isolates from patients are heterogeneous and insensitive to fluconazole. Antimicrob Agents Chemother 2017, 61, e01065-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Auler, M.E.; Morreira, D.; Rodrigues, F.F.O.; Abrão, M.S.; Margarido, P.F.R.; Matsumoto, F.E.; Silva, E.G.; Silva, B.C.M.; Schneider, R.P.; Paula, C.R. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis Biofilm formation on IUDs in patients with vulvovaginal candidiasis. Med. Mycol. 2010, 48, 211–216. [Google Scholar] [CrossRef] [Green Version]
  79. Sobel, J.D. Editorial Commentary: Vaginal Biofilm: Much Ado about Nothing, or a New Therapeutic Challenge? Clin. Infect. Dis. 2015, 61, 607–608. [Google Scholar] [CrossRef] [Green Version]
  80. Yano, J.; Peters, B.M.; Noverr, M.C.; Fidel, P.L. Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: “Neutrophil Anergy. ” Infect. Immun. 2018, 86, e00684-17. [Google Scholar] [CrossRef] [Green Version]
  81. Willems, H.M.E.; Ahmed, S.S.; Liu, J.; Xu, Z.; Peters, B.M. Vulvovaginal candidiasis: A current understanding and burning questions. J. Fungi 2020, 6, 27. [Google Scholar] [CrossRef] [Green Version]
  82. Fidel, P.L. History and update on host defense against vaginal candidiasis. Am. J. Reprod. Immunol. 2007, 57, 2–12. [Google Scholar] [CrossRef]
  83. Roselletti, E.; Perito, S.; Sabbatini, S.; Monari, C.; Vecchiarelli, A. Vaginal Epithelial Cells discriminate between yeast and hyphae of C. albicans in women who are colonized with or have vaginal candidiasis. J. Infect. Dis. 2018, 10, 1645–1654. [Google Scholar] [CrossRef]
  84. Richardson, J.P.; Willems, H.M.E.; Moyes, D.L.; Shoaie, S.; Barker, K.S.; Tan, L.; Palmer, G.E.; Hube, B.; Naglik, J.R.; Peters, M. Candidalysin Drives Epithelial Signaling, Neutrophil Recruitment, and Immunopathology at the Vaginal Mucosa. Infect. Immun. 2018, 86, e00645-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Roselletti, E.; Perito, S.; Gabrielli, E.; Mencacci, A.; Pericolini, E.; Sabbatini, S.; Cassone, A.; Vecchiarelli, A. NLRP3 inflammasome is a key player in human vulvovaginal disease caused by Candida albicans. Sci. Rep. 2017, 7, 17877. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Bruno, V.M.; Shetty, A.C.; Yano, J.; Fidel, P.L.; Noverr, M.C.; Peters, B.M. Transcriptomic Analysis of Vulvovaginal Candidiasis Identifies a Role for the NLRP3 Inflammasome. mBio 2015, 6, e00182-15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.